Tylvalosin

Tylvalosin
Clinical data
Trade names	Aivlosin
AHFS/Drugs.com	Veterinary Use
License data	US DailyMed: Tylvalosin;
Routes of; administration	By mouth
Drug class	Macrolide antibiotic
ATCvet code	QJ01FA92 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	63409-12-1; as tartrate: 63428-13-7;
PubChem CID	6441094;
DrugBank	DB11554; as tartrate: DBSALT001708;
ChemSpider	4945313; as tartrate: 30790860;
UNII	9T02S42WQO; as tartrate: AL5667FY0W;
KEGG	D10032; as tartrate: D10034;
ChEMBL	ChEMBL2103834;
CompTox Dashboard (EPA)	DTXSID901016510 ;
ECHA InfoCard	100.058.284
Chemical and physical data
Formula	C53H87NO19
Molar mass	1042.267 g·mol−1
3D model (JSmol)	Interactive image; as tartrate: Interactive image;
	SMILES CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC; ; as tartrate: O[C@H]([C@@H](O)C(O)=O)C(O)=O.CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC;
	InChI InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1; Key:KCJJINQANFZSAM-HZDSEHBESA-N; ; as tartrate: InChI=1S/C53H87NO19.C4H6O6/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3;5-1(3(7)8)2(6)4(9)10/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3;1-2,5-6H,(H,7,8)(H,9,10)/b18-17+,28-22+;/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-;1-,2-/m11/s1; Key:OLLSDNUHBJHKJS-XKORHJEPSA-N;

Tylvalosin, sold under the brand name Aivlosin, is a macrolide antibiotic used for the treatment of bacterial infections with Mycoplasma hyopneumoniae in swine, that causes enzootic pneumonia.^[3]^[5] It is used as tylvalosin tartrate.^[3]

Mechanism of Action

Macrolides are generally considered to be bacteriostatic agents that exert their antibiotic effect by reversibly binding to the 23S rRNA of the 50S ribosomal subunit, thereby inhibiting bacterial protein synthesis.^[6]

Medical uses

Tylvalosin is indicated for the control of porcine proliferative enteropathy associated with Lawsonia intracellularis infection in groups of swine intended for slaughter and female swine intended for breeding in buildings experiencing an outbreak of PPE.^[3] Not for use in male swine intended for breeding; and for the control of swine respiratory disease associated with Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae in groups of swine intended for slaughter and female swine intended for breeding in buildings experiencing an outbreak of swine respiratory disease.^[3] Not for use in male swine intended for breeding.^[3]

References

^ "Aivlosin- tylvalosin granule". DailyMed. 29 November 2021. Retrieved 13 December 2023.
^ "Aivlosin- tylvalosin tartrate granule, for solution". DailyMed. 29 November 2021. Retrieved 13 December 2023.
^ ^a ^b ^c ^d ^e ^f "Freedom of Information Summary Aivlosin NADA 141-336" (PDF). Retrieved 13 December 2023. This article incorporates text from this source, which is in the public domain.
^ "Aivlosin EPAR". European Medicines Agency (EMA). 8 January 2010. Retrieved 15 October 2024.
^ "Tylvalosin". TOKU-E. Retrieved 28 June 2024.
^ "Tylvalosin". TOKU-E. Retrieved 28 June 2024.